Similarly, an engineered SIRPα-variant-presenting cell membrane-coated magnetic nanoparticle was fabricated to reprogram tumor-associated macrophages (TAMs) and inhibit the CD47-SIRPα pathway, resulting in synergistic activation of the macrophage immune response and controlled tumor progression [13]. The gene discussed is SIRPA; the disease is neoplasm.